AVTX Avalo Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$18.82

Period return

+2.57 (+15.82%)

Volume

1.1M

2026-07-21O $18.11 H $19 L $18.09 C $18.82MA5 $18.57MA20 $18.69MA60 $16.79MA120 $16.02

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 12.Highin 22 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.02%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 14.LowBUY2 months ago
Citizens: Market Outperform
US analyst rating / recommendation change.
2026. 05. 14.LowBUY2 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2026. 05. 14.LowBUY2 months ago
Mizuho: Outperform
US analyst rating / recommendation change.
2026. 05. 14.LowBUY2 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 11.LowBUY2 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2026. 05. 06.LowBUY3 months ago
Citizens: Market Outperform
US analyst rating / recommendation change.
2026. 05. 06.LowBUY3 months ago
Wedbush: Outperform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $46.18 · 11 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
HQ: Wayne, PA, United States
Fiscal year end: —
Employees: 33
IPO date: —

View details →

Top news

Stored first · Google News · Yahoo Finance (English)

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 12.	After market close (AMC)	$-0.63	—	—	$0	—	Scheduled
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-22.63	—	—	$249K	Reported
FY2024 Q3	2023. 09. 30.	Time TBD	—	$-231.05	—	—	$1.35M	Reported
FY2024 Q2	2023. 06. 30.	Time TBD	—	$-338.85	—	—	$1.12M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	916,142	$13.68M	0.02%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	627,502	$11.4M	0.02%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	148,237	$2.69M	0.00%	—	New position
4	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	64,425	$961.87K	0.00%	—	New position

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 14.	Citizens	—	Maintain	Market Outperform → Market Outperform	—	Citizens: Market Outperform
2026. 05. 14.	Wedbush	—	Maintain	Outperform → Outperform	—	Wedbush: Outperform
2026. 05. 14.	Mizuho	—	Maintain	Outperform → Outperform	—	Mizuho: Outperform
2026. 05. 14.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 05. 11.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight
2026. 05. 06.	Citizens	—	Maintain	Market Outperform → Market Outperform	—	Citizens: Market Outperform